


Immune-Related Adverse Event: Myocarditis

Myocarditis is a recognised complication of checkpoint inhibitors. The majority of reported cases have occurred within the first month of therapy. Approximately 1% of patients treated with checkpoint inhibitors develop cardio-toxicity. Myocarditis is associated with a high mortality rate if not treated. It is common for patients to be asymptomatic/ have minimal symptoms and abnormal cardiac tests are significant



Interrupt SACT immunotherapy until discussed with Acute Oncology Team. Please contact on-call oncology/haematology team for advice. Ensure that Acute Oncology/Haematology are informed of admission.

Issue Date: 6 th September 2019	Page 1 of 1	Filename: GAMAMYOC	Version No: 1.0
Author: Anna Olsson-Brown	Authorised by: Immuno-Oncology Committee		Copy No: